Table 2.
aBMD and BMAD During 2 Years of GnRHa Treatment
| Transgirls | ||||||
|---|---|---|---|---|---|---|
| Early Pubertal | Late-Pubertal | |||||
| 0 mo | 24 mo | 0 mo | 24 mo | p1 | p2 | |
| aBMD_LS g/cm2 | 0.73 (0.03) | 0.75(0.03) | 0.79 (0.02) | 0.82 (0.02) | <0.05 | <0.05 |
| Z-score | −0.67 (0.26) | −1.26 (0.24) | −0.33 (0.17) | −0.92 (0.17) | <0.05 | <0.05 |
| aBMD_hip g/cm2 | 0.81 (0.03) | 0.86 (0.03) | 0.87 (0.02) | 0.89 (0.02) | <0.05 | n.s. |
| Z-score | −0.49 (0.24) | −0.93 (0.21) | −0.43 (0.16) | −1.01 (0.15) | <0.05 | <0.05 |
| Whole body BMD g/cm2 | 0.90 (0.02) | 0.92 (0.02) | 0.95 (0.01) | 0.95 (0.01) | <0.05 | n.s. |
| Z-score | −0.56 (0.24) | −1.51 (0.20) | −0.51 (0.16) | −1.62 (0.15) | <0.05 | <0.05 |
| BMAD_LS g/cm3 | 0.20 (0.01) | 0.20 (0.01) | 0.20 (0.01) | 0.21 (0.0!) | n.s. | n.s. |
| Z-score | −0.33 (0.33) | −1.19 (0.34) | −0.65 (0.20) | −1.21 (0.22) | <0.05 | <0.05 |
| BMAD_hip g/cm3 | 0.28 (0.01) | 0.27 (0.01) | 0.28 (0.01) | 0.26 (0.01) | n.s. | <0.05 |
| Z-score | −0.94 (0.27) | −1.23 (0.35) | −1.01 (0.17) | −1.56 (0.25) | n.s. | <0.05 |
| Transboys | ||||||
| Early-pubertal | Late-pubertal | |||||
| 0 mo | 24 mo | 0 mo | 24 mo | p1 | p2 | |
| aBMD_LS g/cm2 | 0.75 (0.03) | 0.80 (0.03) | 0.95 (0.01) | 0.92 (0.01) | <0.05 | <0.05 |
| Z-score | −0.28 (0.27) | −1.04 (0.26) | 0.38 (0.14) | −0.71 (0.14) | <0.05 | <0.05 |
| aBMD_hip g/cm2 | 0.79 (0.03) | 0.83 (0.03) | 0.93 (0.01) | 0.89 (0.02) | <0.05 | <0.05 |
| Z-score | 0.09 (0.26) | −0.50 (0.24) | 0.46 (0.13) | −0.56 (0.13) | <0.05 | <0.05 |
| Whole body BMD g/cm2 | 0.88 (0.02) | 0.92 (0.02) | 1.03 (0.01) | 1.01 (0.01) | <0.05 | <0.05 |
| Z-score | −0.28 (0.27) | −0.82 (0.24) | 0.66 (0.13) | −0.40 (0.13) | <0.05 | <0.05 |
| BMAD_LS g/cm3 | 0.22 (0.01) | 0.22 (0.01) | 0.25 (0.01) | 0.24(0.01) | n.s. | <0.05 |
| Z-score | −0.15 (0.29) | −0.86 (0.30) | 0.33 (0.14) | −0.56 (0.17) | <0.05 | <0.05 |
| BMAD_hip g/cm3 | 0.30 (0.01) | 0.28 (0.01) | 0.32 (0.01) | 0.30 (0.01) | <0.05 | <0.05 |
| Z-score | −0.23 (0.25) | −0.94 (0.30) | 0.04 (0.12) | −0.54 (0.18) | <0.05 | <0.05 |
aBMD and BMAD during 2 years of GnRHa treatment. Values are presented as estimated marginal means ± standard error. p1 represents the P value between the start and after 2 years of treatment for the early pubertal groups. p2 represents the P value between start and after 2 years of treatment for the late-pubertal groups.
For changes per year of treatment see Fig. 1.
Abbreviations: aBMD, areal bone mineral density; BMAD, bone mineral apparent density; BMD, bone mineral density; LS, lumbar spine.